Key Takeaways
- • Brevan Howard, a leading global macro hedge fund, has committed $200 million to Catalio Capital Management's healthcare-focused public equities fund via a separately managed account structure, retaining real-time risk oversight while outsourcing stock selection expertise.
- • Catalio Capital, co-founded by George Petrocheilos and Jacob Vogelstein, has delivered a 49% net return since launch in 2023, with year-to-date performance of 12% net through October 31, 2025, managing $2.3 billion across public and private healthcare investments including pharmaceuticals, medical devices, diagnostics, and data companies.
- • The investment reflects a structural industry shift: the proportion of multi-manager hedge funds allocating capital to external specialist managers has surged from just over 50% in 2022 to nearly 75% by October 2025, according to Goldman Sachs data.
- • The separately managed account structure provides Brevan Howard with position-level visibility, real-time risk monitoring, and faster exit capability compared to traditional locked-in fund vehicles, reducing operational counterparty risk while accessing specialized healthcare sector expertise.
- • Catalio's leadership team includes Ben Snedeker, a former D.E. Shaw portfolio manager, with KKR as a major institutional backer, establishing credibility within the alternative investment ecosystem.
Summary
Brevan Howard, one of the world's most prominent macro hedge fund managers, is deploying $200 million into specialist healthcare equity expertise through a capital allocation to Catalio Capital Management. Rather than building internal healthcare stock-picking capability, Brevan Howard has chosen to outsource equity selection to a dedicated specialist while maintaining structural control through a separately managed account arrangement. This allocation exemplifies a broader industry shift toward multi-manager strategies that blend macro risk management with targeted specialist alpha generation.
Catalio Capital Management, founded in 2023 by George Petrocheilos and Jacob Vogelstein, has established a track record that justifies institutional capital allocation. The firm has generated a 49% net return since inception and posted 12% net performance year-to-date through October 31, 2025. The fund manages $2.3 billion in total assets across both public and private healthcare investments, maintaining exposure to pharmaceuticals, medical devices, diagnostics, and healthcare-focused data companies. The leadership team includes Ben Snedeker, a portfolio manager previously with D.E. Shaw, and the firm counts KKR among its significant institutional backers, providing external validation of operational quality and investment discipline.
The structural mechanics of Brevan Howard's investment merit institutional attention. Rather than committing capital to a traditional hedge fund with limited visibility into underlying positions, Brevan Howard has utilized a separately managed account format that preserves real-time position monitoring, risk exposure assessment, and faster redemption optionality. This architecture allows Brevan Howard to maintain macro-level risk controls over its portfolio exposure while delegating security selection to Catalio's sector specialists, effectively creating a hybrid investment vehicle that balances diversification benefits with retained governance.
The Brevan Howard allocation reflects a quantifiable industry trend documented by Goldman Sachs. The proportion of multi-manager hedge funds that allocate capital to external specialist funds has expanded significantly, rising from approximately 50% in 2022 to nearly 75% by October 2025. This structural shift signals that large multi-strategy platforms increasingly view specialized external managers as more cost-effective and scalable alternatives to building deep sector-specific expertise in-house. For institutional investors, this trend indicates a consolidation of capital around proven specialist managers, increased competition for specialist alpha, and a bifurcation of hedge fund strategies between macro capital allocators and focused specialist performers.
Catalio Capital Management, founded in 2023 by George Petrocheilos and Jacob Vogelstein, has established a track record that justifies institutional capital allocation. The firm has generated a 49% net return since inception and posted 12% net performance year-to-date through October 31, 2025. The fund manages $2.3 billion in total assets across both public and private healthcare investments, maintaining exposure to pharmaceuticals, medical devices, diagnostics, and healthcare-focused data companies. The leadership team includes Ben Snedeker, a portfolio manager previously with D.E. Shaw, and the firm counts KKR among its significant institutional backers, providing external validation of operational quality and investment discipline.
The structural mechanics of Brevan Howard's investment merit institutional attention. Rather than committing capital to a traditional hedge fund with limited visibility into underlying positions, Brevan Howard has utilized a separately managed account format that preserves real-time position monitoring, risk exposure assessment, and faster redemption optionality. This architecture allows Brevan Howard to maintain macro-level risk controls over its portfolio exposure while delegating security selection to Catalio's sector specialists, effectively creating a hybrid investment vehicle that balances diversification benefits with retained governance.
The Brevan Howard allocation reflects a quantifiable industry trend documented by Goldman Sachs. The proportion of multi-manager hedge funds that allocate capital to external specialist funds has expanded significantly, rising from approximately 50% in 2022 to nearly 75% by October 2025. This structural shift signals that large multi-strategy platforms increasingly view specialized external managers as more cost-effective and scalable alternatives to building deep sector-specific expertise in-house. For institutional investors, this trend indicates a consolidation of capital around proven specialist managers, increased competition for specialist alpha, and a bifurcation of hedge fund strategies between macro capital allocators and focused specialist performers.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.